Discovery of the endogenous cannabinoid signalling system unleashed substantial new research into several neurological conditions. A recent systematic review suggests that medical marijuana can improve a number of symptoms—particularly spasticity—in multiple sclerosis, but cannabinoids can have adverse psychological effects and their comparative effectiveness is unknown.
This is a preview of subscription content, access via your institution
Subscribe to this journal
Receive 12 print issues and online access
$189.00 per year
only $15.75 per issue
Rent or buy this article
Get just this article for as long as you need it
Prices may be subject to local taxes which are calculated during checkout
Koppel, B. S. et al. Systematic review: efficacy and safety of medical marijuana in selected neurologic disorders: report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology 82, 1556–1563 (2014).
O'Shaughnessy, W. B. On the preparations of the Indian Hemp, or Gunjah, (Cannabis Indica): their effects on the animal system in health, and their utility in the treatment of tetanus and other convulsive diseases. Prov. Med. J. Retrosp. Med. Sci. 123, 363–369 (1843).
Hosking, R. D. & Zajicek, J. P. Therapeutic potential of cannabis in pain medicine. Br. J. Anaesth. 101, 59–68 (2008).
Nomura, D. K. et al. Endocannabinoid hydrolysis generates brain prostaglandins that promote neuroinflammation. Science 334, 809–813 (2011).
Mestas, J. & Hughes, C. C. Of mice and not men: differences between mouse and human immunology. J. Immunol. 172, 2731–2738 (2004).
Pavisian, B. et al. Effects of cannabis on cognition in patients with MS: a psychometric and MRI study. Neurology 82, 1879–1887 (2014).
Zajicek, J. et al. Effect of dronabinol on progression in progressive multiple sclerosis (CUPID): a randomised, placebo-controlled trial. Lancet Neurol. 12, 857–865 (2013).
Rossi, S. et al. Association between a genetic variant of type-1 cannabinoid receptor and inflammatory neurodegeneration in multiple sclerosis. PLoS One 8, e82848 (2013).
Lazenka, M. F., Selley, D. E. & Sim-Selley, L. J. Brain regional differences in CB1 receptor adaptation and regulation of transcription. Life Sci. 92, 446–452 (2013).
Blazquez, C. et al. Loss of striatal type 1 cannabinoid receptors is a key pathogenic factor in Huntington's disease. Brain 134, 119–136 (2011).
J.Z. has received funding to conduct studies of cannabinoids in multiple sclerosis from the UK Medical Research Council.
J.Z. has received funding from the Institut für klinische Forschung, Berlin, which manufactures Cannador. R.H. declares no competing interests.
Rights and permissions
About this article
Cite this article
Hosking, R., Zajicek, J. Cannabis in neurology—a potted review. Nat Rev Neurol 10, 429–430 (2014). https://doi.org/10.1038/nrneurol.2014.122